Net margin · 2018–2025
Royalty Pharma net margin
32.4%−14.6% · FY2025
Royalty Pharma (RPRX) reported 32.4% in net margin for fiscal 2025, −14.6% year on year.
| Fiscal year | Net margin | Change | Filing |
|---|---|---|---|
| FY2025 | 32.4% | −14.6% | Derived |
| FY2024 | 37.9% | −21.3% | Derived |
| FY2023 | 48.2% | +2,417.5% | Derived |
| FY2022 | 1.9% | −92.9% | Derived |
| FY2021 | 27.1% | −41.1% | Derived |
| FY2020 | 45.9% | −64.5% | Derived |
| FY2019 | 129.4% | +68.6% | Derived |
| FY2018 | 76.8% | — | Derived |
Net margin — Net margin is net income divided by revenue. Only companies with at least $1 billion in revenue are ranked here: a small company can post an extreme margin that tells you nothing.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2018–2025 compound annual growth −11.6%
Calculated from two reported figures, so it has no single filing of its own.
Net margin at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Royalty Pharma net margin |url=https://companiesranked.com/en/company/royalty-pharma/net-profit-margin |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Royalty Pharma net margin. CompaniesRanked. https://companiesranked.com/en/company/royalty-pharma/net-profit-marginBibTeX
@misc{companiesranked-en-company-royalty-pharma-net-profit-margin-2026,
author = {{CompaniesRanked}},
title = {{Royalty Pharma net margin}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/royalty-pharma/net-profit-margin}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.